Jazz Pharmaceuticals - 53 Year Dividend History | JAZZ
Historical dividend payout and yield for Jazz Pharmaceuticals (JAZZ) since 1971. The current TTM dividend payout for Jazz Pharmaceuticals (JAZZ) as of December 20, 2024 is $0.00. The current dividend yield for Jazz Pharmaceuticals as of December 20, 2024 is 0.00%.
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$7.427B |
$3.834B |
|
Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'.
|
| Stock Name |
Country |
Market Cap |
PE Ratio |
